Lantheus Holdings

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and Puerto Rico, third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America, and the EXINI business in Sweden. The company was founded in 1956 and is headquartered in North Billerica, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Lantheus reports record revenues in 2022, eyes sustained growth

Lantheus' strong financial performance and market leadership position it well for continued growth.
While facing competition and investment challenges, Lantheus is focused on innovation and market expansion.
The company's strategic acquisitions, pipeline expansion, and guidance for 2023 signal a positive outlook.
Lantheus aims to maintain profitability while investing in key areas for future growth and market leadership.

Lantheus Holdings reports record Q1 results and eyes oncology growth

Lantheus Holdings delivered robust Q1 results driven by key products, with strong revenue and margin performance.
The company's strategic acquisitions and pipeline advancements position them well for future growth in oncology and Alzheimer's diagnostics.
While facing challenges with certain programs and undisclosed cancer types, Lantheus has outlined clear opportunities for market expansion and new treatment avenues.

Lantheus Holdings excels in Q2, eyes European expansion and innovation

Lantheus Holdings delivered robust Q2 2023 results, showcasing strong revenue growth and operational impact, with raised guidance reflecting confidence in sustained performance.
The company's focus on differentiation, market leadership, and strategic partnerships positions it well for growth despite competitive and regulatory challenges.
Opportunities in expanding market reach, diversification through radiotherapeutic candidates, and product innovation present avenues for future growth and market dominance.
Navigating challenges in competition, regulatory changes, and supply chain optimization will be crucial for Lantheus to maintain its market-leading position and drive continued success.

Lantheus Holdings excels in Q3 with strong revenue growth and market leadership

Lantheus Holdings' strong Q3 performance, driven by robust revenue growth and strategic advancements, positions the company well for future success. Despite challenges such as fixed costs and seasonal fluctuations, Lantheus remains focused on leveraging opportunities in the growing radiopharmaceutical market. With a leading market share, innovative pipeline, and solid financial position, Lantheus is poised for continued growth and value creation.

Lantheus Holdings achieves record revenues, eyes growth in radiopharmaceuticals

Lantheus Holdings delivered strong financial performance in 2023 with record revenues and growth.
The company is strategically positioned to capitalize on opportunities in radiopharmaceuticals and oncology.
Challenges include managing potential product transitions and maintaining market leadership.
Overall, Lantheus shows promise for continued growth and innovation in the healthcare sector.

Lantheus Holdings excels in Q1 2024, eyes $1B sales

Lantheus Holdings delivered a strong performance in Q1 2024, driven by robust sales of PYLARIFY and operational excellence, showcasing financial strength and profitability.
The company's focus on innovation, strategic partnerships, and pipeline opportunities positions it well for future growth and market leadership in radioligand therapy.
While facing challenges in a competitive landscape and evolving industry dynamics, Lantheus has opportunities for revenue growth, market expansion, and strategic collaborations to drive long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

Highlights Piflufolastat F 18's Potential to Change Initial Risk Assessment and Intended Patient Management in High-Risk Prostate Cancer

Lantheus Announces Presentation at the 2021 American Urological Association (AUA) Annual Meeting

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced today that its subsidiary, EXINI Diagnostics AB, was granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its digital application, aPROMISE™ (automated PROstate Cancer Molecular Imaging Standardized Evaluation). Clinicians will have the option to utilize aPROMISE with PYLARIFY® (piflufolastat F 18) to increase the efficiency and reproducibility of their PSMA PET/CT assessm

Lantheus Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE™, Strengthening Lantheus' Leadership in Prostate Cancer

Lantheus Holdings, Inc. (LNTH) CEO Mary Anne Heino on Q2 2021 Results - Earnings Call Transcript

Lantheus Holdings Inc (NASDAQ: LNTH) clocked $101.1 million in sales for Q2 of 2021, beating the consensus of $94.9 million, representing an increase of 53.1% Y/Y. Sales exceeded management's guidance range of $93 million - $97 million.

Lantheus Stock Gains As Q2 Earnings Surpasses Expectations; Raises FY2021 Outlook

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 120.00% and 6.83%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Lantheus Holdings (LNTH) Q2 Earnings and Revenues Beat Estimates

Shares of Lantheus Holdings (NASDAQ:LNTH) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share increased 10.00% over the past year to $0.11, which beat the estimate of $0.05.

Lantheus Holdings: Q2 Earnings Insights

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, today reported financial results for its second quarter ended June 30, 2021. The Company's worldwide revenue for the second quarter of 2021 totaled $101.1 million, compared with $66.0 million for the second

Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results

Lantheus Holdings (LNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Lantheus Holdings (LNTH) to Report a Decline in Earnings: What to Look Out for

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, July 28, 2021, to discuss its financial and operating results for the second quarter of 2021. To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 6149638. A live webcast will also be available in the Invest

Lantheus Holdings to Host Second Quarter 2021 Earnings Conference Call and Webcast on July 28, 2021 at 8:00 a.m. Eastern Time

It has been nearly one year since I took a good look at Lantheus Holdings, but PYLARIFY's approval has forced me to reassess the ticker and my investment strategy. PYLARIFY has the potential to be a game-changer in prostate cancer diagnosis and improve patient outcomes. The company has been hard at work preparing for launch in the USA.

Lantheus Holdings: PYLARIFY Approval Revitalizes My Bullish Outlook

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced that data from the piflufolastat F 18 (formerly known as 18F-DCFPyL) CONDOR pivotal trial will be presented at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI)

Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting

Apellis Pharma

BridgeBio Pharma Inc

Johnson & Johnson

The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive outcomes.

Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates

Lantheus Holdings (LNTH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Lantheus Holdings (LNTH) Soars 16.8%: Is Further Upside Left in the Stock?

Investors are cheering FDA approval for the company's prostate cancer imaging agent.

Why Lantheus Stock Is Soaring Today

The FDA has approved Lantheus Holdings Inc's (NASDAQ: LNTH) Pylarify, a positron emission tomography (PET) imaging agent, to identify suspected metastasis or recurrence of prostate cancer. Pylarify is an F 18-labeled prostate-specific membrane antigen (PSMA) imaging agent for diagnosing prostate cancer.

Lantheus Shares Trading Higher On FDA Approval For Imaging Agent For Identification Of Prostate Cancer

The stock price of Lantheus Holdings Inc (NASDAQ: LNTH) increased by over 20% pre-market. This is why it happened.

LNTH Stock Price: Over 20% Increase Pre-Market Explanation

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today that the U.S. Food and Drug Administration (FDA) has approved PYLARIFY, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging age

Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today a poster presentation featuring data from the Company's Phase 3 CONDOR study at the upcoming 2021 American Society for Clinical Oncology (ASCO) Virtual Meeting, which will be held from

Lantheus Holdings Announces Presentation Featuring 18F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, today announced Mary Anne Heino, President and Chief Executive Officer, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies Virtual Healthcare Conference at 10:30 a.m. ET

Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference

Lantheus Holdings, Inc. (LNTH) CEO Mary Anne Heino on Q1 2021 Results - Earnings Call Transcript

Shares of Lantheus Holdings (NASDAQ:LNTH) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share fell 86.11% over the past year to $0.05, which beat the estimate of ($0.01).

Lantheus Holdings: Q1 Earnings Insights

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, today reported financial results for its first quarter ended March 31, 2021. The Company's worldwide revenue for the first quarter of 2021 totaled $92.5 million, compared with $90.7 million for the first qu

Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--EXINI Diagnostics AB, a subsidiary of Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence (AI) solutions to Find, Fight and Follow serious medical conditions, announced today that it has received CE Mark clearance for aPROMISE in Europe. aPROMISE is artificial intelligence-based, deep learning-enabled, medical device sof

EXINI Diagnostics AB, a Lantheus Company, Receives CE Mark Clearance for aPROMISE in Europe

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today announced a strategic collaboration with Allegheny Health Network (AHN), a western Pennsylvania healthcare delivery system headquartered in Pittsburgh, PA. Under the agreement, Lantheus' microbubbles

Lantheus Grants Allegheny Health Network Exclusive Rights for the Use of its Microbubbles in Combination with Ultrasound Assisted Gene Therapy for the Development of a Proposed Treatment for Xerostomia

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Tuesday, May 4, 2021, to discuss its financial and operating results for the first quarter of 2021. To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1‑678-509-7599 (international callers) and provide passcode 9275247. A live webcast will also be available in the Investors s

News for Lantheus Holdings Stock (LNTH)